A narrow spectrum macrocyclic antibiotic drug.
A fermentation product obtained from the actinomycete Dactylosporangium aurantiacum subspecies hamdenesis.
A non-systemic antibiotic, which is bactericidal,
Fidaxomicin is an oral macrocyclic anti-biotic with minimal systemic absorption, and a narrow spectrum of activity against gram-positive aerobic and anaerobic bacteria.
Selective eradication of pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora.
Reduces the probability of Clostridium difficile infection recurrence.
Administered orally.
Inhibits the bacterial enzyme RNA polymerase, resulting in the death of Clostridium difficile, and is active against gram positive bacteria.
Minimal inhibitory concentration (MIC) range for C. difficile is 0.03–0.25(μg/mL), and 13.3% of the subjects had a recurrence with fidaxomicin vs. 24.0% with oral vancomycin.
Trade name Dificid
Oral agent with minimal systemic absorption.
Half-life of 11.7 ± 4.80 hours.
Urine excretion less than 1%, and feces 92%.
A narrow spectrum macrocyclic antibiotic drug.
Is bactericidal, with selective eradication of pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora.
Fidaxomicin is more efficacious when used earlier in CDI management.
Can reduce the probability of Clostridium difficile infection recurrence.
Used for treatment of Clostridium difficile infection.
Dose of 200 mg tablets administered every 12 hours for 10 days, determined by the patient’s clinical status.
Inhibits the bacterial enzyme RNA polymerase, active against Gram positive bacteria especially clostridia.
The minimal inhibitory concentration (MIC) range for C. difficile is 0.03–0.25 μg/mL.
When comparing it with oral vancomycin for the treatment of Clostridium difficile infection (CDI) fidaxomicin is non-inferior to oral vancomycin (92.1% vs. 89.8%).